Status:
COMPLETED
Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Conditions:
Infertility
Eligibility:
FEMALE
18-35 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and ot...
Detailed Description
Within the new guidelines for stimulation, the use of oral progesterone in follicular phase allows GnRH analogue administration, resulting in greater comfort for patients as well as a reduction in cos...
Eligibility Criteria
Inclusion
- Age between 18-35 years (both included)
- Regular Menses (between 25-35 days)
- Absence of physical and psychic pathologies at the time of oocyte donation
- BMI: 18-28 kg(m2 at the time of oocyte donation.
- Other criteria to comply with:
- i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view:
- Healthy ovaries and uterus, with no organic pathology
- Ovaries without polycystic aspect
- Antral Follicle Count \> 12 in the sum of both ovaries
- Normal Karyotype
- Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)
- Results within range of general analysis of hemogram, hemostasia y biochemistry.
Exclusion
- Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines
- Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension
- Severe hepatic insufficiency, cardiovascular illness
- Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs
- Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus
- Known hypersensitivity to PMA or its excipients
- Any reason or cause which excluede from the oocyte donation program
- Participation in another clinical trial in the two months prior to the inclusion on this study
Key Trial Info
Start Date :
October 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2019
Estimated Enrollment :
318 Patients enrolled
Trial Details
Trial ID
NCT03300960
Start Date
October 20 2017
End Date
June 25 2019
Last Update
August 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IVI Valencia
Valencia, Spain, 46015